VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XERSXeris Biopharma Holdings, Inc.
$16.99$2.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXERSP/E History

XERS logoXeris Biopharma Holdings, Inc. (XERS) P/E Ratio History

Deep Value

Trading at -496.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2026–2026

Current P/E (TTM)
-496.8x
-657% vs 5Y avg
5Y Avg P/E
89.2x
Median 89.2x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-0.03
Price$16.99
Earnings YieldN/A
EPS Growth (1Y)100.9%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of November 19, 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a price-to-earnings ratio of -496.8x, with a stock price of $16.99 and trailing twelve-month earnings per share of $-0.03.

The current P/E is 657% below its 5-year average of 89.2x. Over the past five years, XERS's P/E has ranged from a low of 89.2x to a high of 89.2x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.7x, XERS trades at a 2114% discount to its sector peers. The sector includes 252 companies with P/E ratios ranging from 0.0x to 187.0x.

Relative to the broader market, XERS trades at a notable discount to the S&P 500 median P/E of 21.7x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XERS DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

XERS Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-496.8vs24.7
-2114%
Below Sector
vs. S&P 500
-496.8vs21.7
-2390%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 101% EPS growth (1Y)

XERS P/E vs Peers

Rare Disease Commercial Leaders peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
LNTH logoLNTHLantheus Holdings, Inc.
$7B25.9--22%
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$4B7.9Lowest-+10833%Best
PAHC logoPAHCPhibro Animal Health Corporation
$1B14.21.11+105%
CORT logoCORTCorcept Therapeutics Incorporated
$7B51.6--33%
AMRX logoAMRXAmneal Pharmaceuticals, Inc.
$7B49.8-+158%
NVO logoNVONovo Nordisk A/S
$175B10.50.51Best+2%
LLY logoLLYEli Lilly and Company
$1.3T44.81.55+96%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

XERS Historical P/E Data (2026–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$5.80$0.0789.2x+0%

Average P/E for displayed period: 89.2x

Export Data
Consensus & Technical Research Suite
Open XERS Terminal

XERS Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

XERS — Frequently Asked Questions

Quick answers to the most common questions about buying XERS stock.

What is XERS's P/E ratio?

Xeris Biopharma Holdings, Inc. (XERS) trailing twelve-month P/E ratio is -496.8x, based on TTM diluted EPS of $-0.03. The 5-year average P/E is 89.2x and the historical range spans 89.2x to 89.2x.

Is XERS stock overvalued or undervalued?

XERS trades at -496.8x P/E, below its 5-year average of 89.2x. At the 0th percentile of its historical range (89.2x–89.2x), the stock is priced at a discount to its own history.

Is XERS stock expensive?

No, XERS is not expensive on a historical basis. The current P/E of -496.8x is below the 5-year average of 89.2x and sits at the 0th percentile of its valuation range.

What is XERS's historical P/E range?

Over the past 5 years, XERS's P/E ratio has ranged from 89.2x to 89.2x, with a median of 89.2x and an average of 89.2x. The current P/E of -496.8x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.

How does XERS's P/E compare to the S&P 500?

XERS trades at -496.8x P/E versus the S&P 500 median of 21.7x. The 2389% discount to the market suggests lower growth expectations or perceived higher risk.

How does XERS's valuation compare to Healthcare peers?

Xeris Biopharma Holdings, Inc. P/E of -496.8x compares to the Healthcare sector median of 24.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is XERS's PEG ratio?

XERS PEG ratio is N/A, based on a P/E of -496.8x and EPS growth of 100.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is XERS's earnings yield?

XERS earnings yield is N/A, the inverse of its -496.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

XERS P/E Ratio History (2026–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current89.2x
Period Avg89.2x
Range89.2x - 89.2x
Change+0%
1 quartersMar 31, 2026 - Mar 31, 2026